ライフサイエンスコーパス: extrapyramidal symptom

1 isorders comprising cerebellar ataxia and/or extrapyramidal symptoms.

2 sedation, akathisia (for aripiprazole), and extrapyramidal symptoms.

3 dverse events at the injection site and more extrapyramidal symptoms.

4 performance and shows reduced liability for extrapyramidal symptoms.

5 toms without marked positive, depressive, or extrapyramidal symptoms.

6 oncentration correlated with the severity of extrapyramidal symptoms.

7 renia (PNS), and minimal positive/depressive/extrapyramidal symptoms.

8 rates of dysphoria, depressive symptoms, and extrapyramidal symptoms.

9 t is clinically effective with a low risk of extrapyramidal symptoms.

10 mptoms of schizophrenia; quality of life; or extrapyramidal symptoms.

11 impson-Angus Rating Scale was used to assess extrapyramidal symptoms.

12 onventional antipsychotic agents in terms of extrapyramidal symptoms.

13 e apparently unrelated subjects with similar extrapyramidal symptoms.

14 events and the use of medications related to extrapyramidal symptoms.

15 There was minimal risk of extrapyramidal symptoms.

16 e risperidone and olanzapine groups reported extrapyramidal symptoms (24% and 20%, respectively).

17 One subject experienced moderate extrapyramidal symptoms (akasthisia) during RWJ-37796 in

18 Extrapyramidal symptoms and akathisia were similar in th

19 The incidence of extrapyramidal symptoms and changes in the levels of lip

20 nd because treatment is often accompanied by extrapyramidal symptoms and dyskinesias.

21 Safety and tolerability evaluations included extrapyramidal symptoms and effects on weight, prolactin

22 otic agents in producing significantly fewer extrapyramidal symptoms and having a lower risk of tardi

23 that has associated chronic cocaine use with extrapyramidal symptoms and striatal dopaminergic deplet

24 ated patients had a significant reduction in extrapyramidal symptoms and subjective measures of stiff

25 psychotic medications should be examined for extrapyramidal symptoms and tardive dyskinesia.

26 in the domains of symptoms, quality of life, extrapyramidal symptoms, and a synthetic measure of mult

27 ant even after lifetime medication exposure, extrapyramidal symptoms, and abnormal involuntary moveme

28 Anticholinergic use, extrapyramidal symptoms, and estimated IQ had little eff

29 and negative symptoms, comorbid depression, extrapyramidal symptoms, and overall drug safety.

30 athy, clubfoot, absent deep tendon reflexes, extrapyramidal symptoms, and persistently deficient myel

31 events, laboratory parameters, vital signs, extrapyramidal symptoms, and suicidality.

32 ncluding weight gain, metabolic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especi

33 s on overall psychopathology, response rate, extrapyramidal symptoms, and tardive dyskinesia.

34 Three rating scales were used to assess extrapyramidal symptoms as well as the occurrence of adv

35 ol-treated patients experienced worsening of extrapyramidal symptoms, as indicated by several measure

36 nternational Neuropsychiatric Interview, and extrapyramidal symptom assessments indicating normal to

37 % of treated patients develop characteristic extrapyramidal symptoms caused by haloperidol-induced to

38 Safety was assessed using adverse events, Extrapyramidal Symptom (EPS) rating scales, laboratory v

39 or antipsychotic drugs which will not induce extrapyramidal symptoms (EPS) and tardive dyskinesias (T

40 ng there is a potential risk of exacerbating extrapyramidal symptoms (EPS) if H3R antagonists were us

41 regard to both the antipsychotic action and extrapyramidal symptoms (EPS) of antipsychotic drugs (AP

42 scular events, as well as metabolic effects, extrapyramidal symptoms, falls, cognitive worsening, car

43 th anti-NMDA receptor antibodies both showed extrapyramidal symptoms following initiation of treatmen

44 and is necessary to reduce the expression of extrapyramidal symptoms induced by chronic haloperidol t

45 Safety measures included adverse events, extrapyramidal symptoms, laboratory assessments, and sui

46 safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalep

47 For all extrapyramidal symptom measures, sertindole was clinical

48 tolerated and associated with a low rate of extrapyramidal symptoms; neither weight gain nor clinica

49 H] = 87), stroke (NNH = 53 for risperidone), extrapyramidal symptoms (NNH = 10 for olanzapine; NNH =

50 se of atypical features, including exclusive extrapyramidal symptoms, normal eye movements, and norma

51 patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events.

52 es carrying a single parkin mutation without extrapyramidal symptoms or signs also had psychiatric sy

53 atients with respect to prolactin elevation, extrapyramidal symptoms or weight gain.

54 ignificant cognitive impairment, increase in extrapyramidal symptoms, or central anticholinergic effe

55 y differential effects on positive symptoms, extrapyramidal symptoms, or mood).

56 but not with age, gender, negative symptoms, extrapyramidal symptoms, or neuroleptic dose.

57 lactic benztropine) in compliance, symptoms, extrapyramidal symptoms, or overall quality of life, and

58 Although olanzapine is associated with fewer extrapyramidal symptoms, other side effects may offset t

59 rrected QT-interval prolongation (p = 0.16), extrapyramidal symptoms (p = 0.31), excessive sedation (

60 These findings support an atypical extrapyramidal symptom profile and the potential of a si

61 to explain the therapeutic efficacy and low extrapyramidal symptom profile of atypical antipsychotic

62 The extrapyramidal symptom profile of risperidone was compar

63 elated to 1) change in negative symptoms, 2) extrapyramidal symptom profile, 3) effect on prolactin l

64 There were no significant changes in Extrapyramidal Symptom Rating Scale scores and no cases

65 While Extrapyramidal Symptom Rating Scale scores were signific

66 Extrapyramidal Symptom Rating Scale total scores at endp

67 am and laboratory results, and scores on the Extrapyramidal Symptom Rating Scale.

68 to scores on the dyskinesia subscale of the Extrapyramidal Symptom Rating Scale.

69 Rating Scale, the Mini-Mental State, and the Extrapyramidal Symptom Rating Scale.

70 placebo in mean change from baseline in the extrapyramidal symptom rating scales.

71 rom baseline in lipid and glucose levels and extrapyramidal symptom ratings.

72 The incidence of extrapyramidal symptom-related treatment-emergent advers

73 rious side effects and significantly greater extrapyramidal symptoms relative to pimozide.

74 ter TTR (SMD=-0.27) and a lower incidence of extrapyramidal symptoms (RR=0.31, NNH=7) compared with h

75 hisia Scale, and Modified Simpson-Angus [for Extrapyramidal Symptoms] Scale) and electromechanical as

76 ssessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at

77 luded spontaneously reported adverse events, extrapyramidal symptom scores, serum prolactin concentra

78 Extrapyramidal symptom severity scores were 1.4 (95% CI=

79 Extrapyramidal symptoms (Simpson-Angus Scale, Barnes Aka

80 iapine was well tolerated and did not induce extrapyramidal symptoms, sustained elevations of prolact

81 experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multipl

82 s of haloperidol produced significantly more extrapyramidal symptoms than placebo or sertindole.

83 at improvement in positive, negative, and/or extrapyramidal symptoms was associated with mood improve

84 Severity of extrapyramidal symptoms was low in both groups, with no

85 Severity of extrapyramidal symptoms was mild at baseline and through

86 hereas the incidence of QTc prolongation and extrapyramidal symptoms was similar between groups, more

87 ebo group (p = .60), and a global measure of extrapyramidal symptoms was similar between treatment gr

88 Measures of extrapyramidal symptoms, weight gain, and somnolence wer

89 Extrapyramidal symptoms were assessed using the Simpson-

90 indistinguishable from placebo, and rates of extrapyramidal symptoms were not dose related.

91 f somnolence, weight gain, restlessness, and extrapyramidal symptoms were similar in the two groups.

92 The frequency and severity of extrapyramidal symptoms were similar in the two treatmen

93 Adverse events related to extrapyramidal symptoms were spontaneously reported by 1

94 owever, haloperidol carries a higher rate of extrapyramidal symptoms, whereas olanzapine is associate